HES and Acute Kidney Injury in Adult Cardiac Surgery

NCT ID: NCT02445820

Last Updated: 2015-10-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

697 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-11-30

Study Completion Date

2015-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study retrospectively assess the effect or using balanced hydroxyethyl sctarch (HES) 130/0.4 or a balanced crystalloid solution as a pump prime and for intraoperative fluid therapy on the risk of early acute postoperative kidney injury in adult cardiac surgery patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury After Adult Cardiac Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HES

Balanced HES 130/0.4 used as and pump prime and for intraoperative fluid therapy.

HES

Intervention Type DRUG

2500 mL of balanced HES 130/0.4

Crystalloid

Balanced Crystalloid used as a pump prime and for intraoperative fluid therapy.

Crystalloid

Intervention Type DRUG

2500 mL of balanced crystalloid.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HES

2500 mL of balanced HES 130/0.4

Intervention Type DRUG

Crystalloid

2500 mL of balanced crystalloid.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Volulyte® Plasmalyte A ®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 yo
* Having on pump cardiac surgery at CHU of Liège between April 2013 and June 2014

Exclusion Criteria

* Off pump surgery
* Use of Blood or Albumin in the cardiopulmonary bypass priming solution
* Preoperative dialysis
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Liege

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jean François Brichant

Professor of Anesthesia and Intensive Care Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ANES2015002

Identifier Type: -

Identifier Source: org_study_id